ABVC BioPharma Receives $566,000 in Cumulative Payments Under Vitargus Licensing Agreement
ABVC BioPharma has received cumulative payments of $566,000 from ForSeeCon Eye Corporation under their Vitargus licensing agreement, with the funds supporting GMP facility preparation for the biodegradable vitreous substitute's production.
ABVC BioPharma has received a $70,000 licensing payment from partner ForSeeCon Eye Corporation under their global licensing agreement for Vitargus, the world's first biodegradable vitreous substitute. This latest payment brings the cumulative total received under the agreement to $566,000, representing progress toward the agreement's potential total value of up to $93.5 million, including $3.5 million in cash licensing payments, up to $30 million in equity consideration, and up to $60 million in future royalties.
The financial impact of ABVC's licensing strategy has been substantial, with the company receiving a total of $1,345,950 in licensing revenues across all current partnerships since the start of fiscal 2025. These revenues come with minimal incremental costs as development expenses were largely incurred in prior years, resulting in high-margin revenues that directly enhance the company's financial position while supporting strategic reinvestments.
ABVC will allocate the new licensing income to its Good Manufacturing Practice pharmaceutical facility in Hsinchu, Taiwan, specifically preparing for GMP-compliant production of Vitargus. This facility represents a critical milestone in moving the product from development into scalable, regulatory-compliant manufacturing necessary for future commercialization. The global vitreous substitute market is estimated at $2.5 billion in 2024 and projected to grow to $4.1 billion by 2033 according to market research.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the company has secured $1.35 million in licensing revenues across multiple partnerships in 2025 alone. These high-margin revenues enable direct reinvestment into the Hsinchu GMP facility, where groundwork is being laid for Vitargus GMP-compliant production as a critical step toward commercialization and delivering long-term shareholder value.
ABVC's licensing framework with multiple partners, including AiBtl, ForSeeCon, and OncoX, positions the company to capture both near-term liquidity and long-term growth opportunities in central nervous system disorders, oncology, and ophthalmology. The company has potential to receive more than $12 million in future receivables through these partnerships. ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device under development, utilizing in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.